We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




New Antibiotic Kills Pathogens Without Detectable Resistance

By HospiMedica International staff writers
Posted on 20 Jan 2015
Print article
Image: The iChip being removed from soil (Photo courtesy of Northeastern University).
Image: The iChip being removed from soil (Photo courtesy of Northeastern University).
The first new antibiotic to be discovered in nearly 30 years could revolutionize the fight against the growing antibiotic resistance, claims a new study.

Researchers at the University of Bonn (Germany), Northeastern University (Boston, MA, USA), and other institutions have discovered a new antibiotic, which they named teixobactin, which inhibits cell wall synthesis by binding to lipid II, and is different in its action than other glycopeptide drugs, such as vancomycin or dalbavancin. Teixobactin was highly effective against common Gram positive bacteria, such as Clostridium difficile, Mycobacterium tuberculosis, and Staphylococcus aureus, but was ineffective against Gram negative pathogens.

The discovery was made possible using a new technique called the iChip, which is made of a lattice of wells holding individual bacteria within agar. Once loaded with bacteria, the iChip is covered with a permeable membrane and replaced into the original soil. Using the technique, the researchers were able to screen 10,000 previously unculturable bacteria, discovered a new bacteria, Eleftheria terrae, and 25 new compounds, among them teixobactin, the most promising one to date.

In mouse studies, teixobactin showed 100% efficacy against methicillin-resistant Staphylococcus aureus (MRSA) sepsis in thigh infection, and was very active against S. pneumoniae in lungs. No toxicity and no hemolytic activity were seen against the mammal cells tested, and the drug did not bind DNA, leading the researchers to be optimistic about its overall toxicity. The first clinical trials on humans could begin in two years and, if successful, the drug could be in widespread use in 10 years. The study describing teixobactin and the iChip was published on January 7, 2015, in Nature.

“Bacteria develop resistance by mutations in their proteins. The targets of teixobactin are not proteins, they are polymer precursors of cell wall building blocks so there is really nothing to mutate,” said senior author, Prof. Kim Lewis, PhD, director of the antimicrobial discovery center at Northeastern University. “Apart from the immediate implementation, there is also, I think, a paradigm shift in our minds, because we have been operating on the basis that resistance development is inevitable and that we have to focus on introducing drugs faster than resistance.”

The “golden age” of antibiotic discovery was achieved by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s, since 99% of microbes will not grow in laboratory conditions. The advent of the iChip could aid growing the microbes in the soil, and then isolating their antibiotic chemical compounds.

Related Links:

University of Bonn
Northeastern University


Gold Member
12-Channel ECG
CM1200B
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Breast Imaging Workstation
SecurView

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.